Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Rice

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Leukemia & Lymphoma|February 1, 2017
Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis - a retrospective study from a tertiary centerXinyu Nan, Qian Qin, Cesar Gentille, et al.
Archives of Internal Medicine|January 14, 2004
Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopeniaAbhay F Srinivasan, Lawrence Rice, John R Bartholomew, et al.
British Journal of Haematology|January 5, 2008
P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cellsJianguo Wen, Haiyun Y Cheng, Yongdong Feng, et al.
British Journal of Haematology|November 20, 2008
Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trialsJames N George, Susan D Mathias, Ronald S Go, et al.
Blood Advances|November 23, 2018
Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopeniaAllyson M Pishko, Sara Fardin, Daniel S Lefler, et al.
Leukemia Research|July 18, 2009
Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibitionJianguo Wen, Yongdong Feng, Wanting Huang, et al.
Journal of Thrombosis and Haemostasis : JTH|July 28, 2019
The risk of major bleeding in patients with suspected heparin-induced thrombocytopeniaAllyson M Pishko, Daniel S Lefler, Phyllis Gimotty, et al.
Blood|September 16, 2017
Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpuraMarie Scully, Paul Knöbl, Karim Kentouche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemiaEttore Biagi, Raphael Rousseau, Eric Yvon, et al.
Journal of Cardiac Failure|January 15, 2016
Acquired and Hereditary Hypercoagulable States in Patients with Continuous Flow Left Ventricular Assist Devices: Prevalence and Thrombotic ComplicationsPaulino Alvarez, Andrea M Cordero-Reyes, Cesar Uribe, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Leukemia & Lymphoma|February 1, 2017
Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis - a retrospective study from a tertiary centerXinyu Nan, Qian Qin, Cesar Gentille, et al.
Archives of Internal Medicine|January 14, 2004
Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopeniaAbhay F Srinivasan, Lawrence Rice, John R Bartholomew, et al.
British Journal of Haematology|January 5, 2008
P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cellsJianguo Wen, Haiyun Y Cheng, Yongdong Feng, et al.
British Journal of Haematology|November 20, 2008
Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trialsJames N George, Susan D Mathias, Ronald S Go, et al.
Blood Advances|November 23, 2018
Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopeniaAllyson M Pishko, Sara Fardin, Daniel S Lefler, et al.
Leukemia Research|July 18, 2009
Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibitionJianguo Wen, Yongdong Feng, Wanting Huang, et al.
Journal of Thrombosis and Haemostasis : JTH|July 28, 2019
The risk of major bleeding in patients with suspected heparin-induced thrombocytopeniaAllyson M Pishko, Daniel S Lefler, Phyllis Gimotty, et al.
Blood|September 16, 2017
Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpuraMarie Scully, Paul Knöbl, Karim Kentouche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemiaEttore Biagi, Raphael Rousseau, Eric Yvon, et al.
Journal of Cardiac Failure|January 15, 2016
Acquired and Hereditary Hypercoagulable States in Patients with Continuous Flow Left Ventricular Assist Devices: Prevalence and Thrombotic ComplicationsPaulino Alvarez, Andrea M Cordero-Reyes, Cesar Uribe, et al.
Pageof 6